Immunohistochemical Evaluation of SOX-10 in Patients with Urinary Bladder Cancer
1
Department of Basic Sciences, University of Kufa, Collage of Dentistry, Kufa, Iraq, Iraq
2
Department of General Pathology and Forensic Medicine, University of Kufa, Iraq
Submission date: 2023-12-30
Final revision date: 2024-08-12
Acceptance date: 2024-11-12
Publication date: 2024-12-30
Corresponding author
Randa Saad Hameed
Department of Basic Sciences, University of Kufa, Collage of Dentistry, Kufa, Iraq, Iraq
Department of Basic Sciences, University of Kufa, Collage of Dentistry, Kufa, Iraq, Iraq
Wiadomości Lekarskie 2024;77(12):2481-2486
KEYWORDS
TOPICS
ABSTRACT
Aim:
Aims: To evaluate the expression levels of Sox10 in tissues of bladder tumor and to prove the correlation between Sox10 expression and clinicopathological characteristics of bladder tumors, including patient age, sex, tumor grade, and muscle invasion.
Material and methods:
Material and Method: Forty formalin fixed paraffin embedded FFPE tissue blocks gathered by transurethral resection of bladder tumor are collected from teaching hospitals at Al-Najaf governorate. Those blocks were stained by hematoxylin and eosin. The histopathological characteristics were examined and immunostained by SOX-10.
Results:
Results: An assessment of expression of SOX-10 in carcinoma of urothelium showed that a test of SOX-10 was (positive) in five samples of urothelial carcinoma, while SOX-10 test was (negative) in thirty-five samples of urothelial carcinoma. Correlation of SOX-10 with other variables (age, sex, and grade) was a statistically non-significant.
Conclusions:
Conclusion: SOX-10 is an Immunohistochemical sensitive marker for the diagnosis of urothelial carcinoma. SOX-10 expression appeared to be non-significant relation with age, gender and histopathological parameters and its expression has been showed to be lost or decreased in substantial proportion in relation to urothelial carcinoma. This variation or down regulation of SOX-10 is correlated with higher tumor grade and stage.
Aims: To evaluate the expression levels of Sox10 in tissues of bladder tumor and to prove the correlation between Sox10 expression and clinicopathological characteristics of bladder tumors, including patient age, sex, tumor grade, and muscle invasion.
Material and methods:
Material and Method: Forty formalin fixed paraffin embedded FFPE tissue blocks gathered by transurethral resection of bladder tumor are collected from teaching hospitals at Al-Najaf governorate. Those blocks were stained by hematoxylin and eosin. The histopathological characteristics were examined and immunostained by SOX-10.
Results:
Results: An assessment of expression of SOX-10 in carcinoma of urothelium showed that a test of SOX-10 was (positive) in five samples of urothelial carcinoma, while SOX-10 test was (negative) in thirty-five samples of urothelial carcinoma. Correlation of SOX-10 with other variables (age, sex, and grade) was a statistically non-significant.
Conclusions:
Conclusion: SOX-10 is an Immunohistochemical sensitive marker for the diagnosis of urothelial carcinoma. SOX-10 expression appeared to be non-significant relation with age, gender and histopathological parameters and its expression has been showed to be lost or decreased in substantial proportion in relation to urothelial carcinoma. This variation or down regulation of SOX-10 is correlated with higher tumor grade and stage.
REFERENCES (27)
1.
Bray F, Ferlay J, Soerjomataram U et al. Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;(68):394-424. DOI: 10.3322/caac.21492.
2.
Apolo AB, Vogelzang NJ, Theodorescu D. New and promising strategies in the management of bladder cancer. Am Soc Clin Oncol. 2015; (35): 105-112.
3.
Wyszynski A, Tanyos SA, Rees JR et al. Body mass and smoking are modifiable risk factors for recurrent bladder cancer. Cancer. 2014;120(3):408–414. DOI: 10.1002/cncr.28394.
4.
Calle EE, Rodriguez C, Walker-Thurmond K et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–1638. DOI: 10.1056/NEJMoa.021423.
5.
Ramos JR, Pabijan J, Garcia R et al. The softening of human bladder cancer cells happens at an early stage of the malignancy process. Beilstein J Nanotechnol. 2014;5:447–457. DOI: 10.3762/bjnano.5.52.
6.
Agarwal H, Babu S, Rana C et al. Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma. Indian J Pathol Microbiol. 2019;62:244-250. DOI: 10.4103/IJPM.IJPM.22818.
7.
Leivo MZ, Elson PJ, Tacha DE et al. A combination of p40, GATA 3 and uroplakin II shows utility in the diagnosis and prognosis of muscle invasive urothelial carcinoma. Pathology. 2016;48:543-549. DOI:10.1016/j.pathol.2016.05.008.
8.
Narter F, Tarhan F, Saglam E. Importance of the Re-transurethral resection in bladder cancer treatment. Bullet of Urooncol .2016;15:94-97. DOI: 10.1016/j.juro.2014.01.087.
9.
Kamat AM, Hahn NM, Efstathiou JA et al. Bladder cancer. Lancet .2016;388:2796-2810. DOI: 10.1016/S0140-6736(16)30512-8.
10.
Silnitsky S, Rubin SJS, Zerihun M et al. An update on protein kinases as therapeutic targets-part I: protein kinase C activation and its role in cancer and cardiovascular diseases. Int J Mol Sci. 2023;24(24):17600. DOI: 10.3390/ijms.242417600.
11.
Nedjadi T, Ahmed ME, Ansari HR et al. Identification of SPP1 as a prognostic biomarker and immune cells modulator in urothelial bladder cancer: a bioinformatics analysis. Cancers (Basel). 2023;15(23):5704. DOI: 10.3390/cancers.15235704.
12.
Wang G, McKenney JK. Urinary bladder pathology: World Health Organization Classification and American Joint Committee on Cancer Staging Update. Arch Pathol Lab Med. 2019;143:571-577. DOI: 10.5858/arpa.2017-0539-RA.
13.
Zhang L, Yang G, Zhang R. Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells. Int J Oncol. 2018;53(2):515–526. DOI: 10.3892/ijo.2018.4423.
14.
Prijovic N, Acimovic M, Santric V et al. Predictive value of inflammatory and nutritional indexes in the pathology of bladder cancer patients treated with radical cystectomy. Curr Oncol. 2023;30(3):2582-2597. DOI: 10.3390/curronco.l30030197.
15.
Li Y, Chen T, Fu B et al. Survival nomogram for high-grade bladder cancer patients after surgery based on the SEER database and external validation cohort. Front Oncol. 2023;13:1164401. DOI: 10.3389/fonc.2023.1164401.
16.
Miyahara K, Kato Y, Koga H et al. Visualization of enteric neural crest cell migration in SOX-10 transgenic mouse gut using time-lapse fluorescence imaging. J Pediatr Surg. 2011;46(12):2305–2308. DOI: 10.1016/j.jpedsurg.2011.09.020.
17.
Mollaaghababa R, Pavan WJ. The importance of having your SOX on: role of SOX10 in the development of neural crest-derived melanocytes and glia. Oncogene.2019;22(20):3024-3034. DOI: 10.1038/sj.onc.1206442.
18.
Wenzhi H, Ruijin W, Jieliang L et al. Heterozygous deletion at the SOX10 gene locus in two patients from a Chinese family with Waardenburg syndrome type II. Int J Pediatr Otorhinolaryngol. 2015;79(10):1718–1721. DOI: 10.1016/j.ijporl.2015.07.034.
19.
Panaccione A, Chang MT, Carbone BE et al. NOTCH1 and SOX10 are essential for proliferation and radiation resistance of cancer stem-like cells in adenoid cystic carcinoma. Clin Cancer Res. 2016;22(8):2083–2095. DOI: 10.1158/1078-0432.CCR-15-2208.
20.
Lopez-Anido C, Sun G, Koenning M et al. Differential SOX10 genomic occupancy in myelinating glia. Glia. 2015;63(11):1897–914. DOI: 10.1002/glia.22855.
21.
Nicoletti C, Wei X, Etxaniz U et al. Muscle denervation promotes functional interactions between glial and mesenchymal cells through NGFR and NGF. iScience. 2023;26(7):107114. DOI: 10.1016/j.isci.2023.107114.
22.
Zhang Y, Shen Y, Zhao L et al. Transcription Factor BCL11A Regulates Schwann Cell Behavior During Peripheral Nerve Regeneration. Mol Neurobiol. 2023;60(9):5352-5365. DOI: 10.1007/s12035-023-03432-6.
23.
Duong P, Ramesh R, Schneider A et al. Modulation of Schwann cell homeostasis by the BAP1 deubiquitinase. Glia. 2023;71(6):1466-1480. DOI: 10.1002/glia.24351.
24.
Selcen I, Prentice E, Casaccia P. The epigenetic landscape of oligodendrocyte lineage cells. Ann N Y Acad Sci. 2023;1522(1):24-41. DOI: 10.1111/nyas.14959.
25.
Yin H, Qin C, Zhao Y. SOX10 is over-expressed in bladder cancer and contributes to the malignant bladder cancer cell behaviors. Clin Transl Oncol. 2017;19:1035-1044. DOI: 10.1007/s12094-017-1641-2.
26.
Li C, Cheng B, Yang X et al. SOX8 promotes tumor growth and metastasis through FZD6-dependent Wnt/β-catenin signaling in colorectal carcinoma. Heliyon. 2023;9(12):e22586. DOI: 10.1016/j.heliyon.2023.e22586.
27.
Yin H, Qin C, Zhao Y et al. SOX10 is over-expressed in bladder cancer and contributes to the malignant bladder cancer cell behaviors. Clin Transl Oncol. 2017;19:1035–1044.
| eISSN: | 2719-342X |
| ISSN: | 0043-5147 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
